ArticleCancer science2026
Elucidating PI3K/AKT/PTEN Pathway Alterations at Single-Cell Level in CTCs From HR+/HER2- Metastatic Breast Cancer.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alterations in the PI3K signaling pathway are common in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (MBC) and are associated with response to PI3K and AKT inhibitor-targeted therapies. When metastasis biopsy is unavailable for genetic testing, circulating tumor DNA (ctDNA) analysis is an alternative strategy for tumor genotyping, but it is less sensitive for gain and loss analysis. Here, we assess molecular alterations of the genes of this axis-PIK3CA, AKT1, and PTEN-in circulating tumor cells (CTCs) from patients with HR+/HER2- MBC. CTCs from blood were isolated as single cells with DEPArrayNxT. Libraries were prepared for copy number analysis (CNA) and investigation of PIK3CA, AKT1, and PTEN mutational status. A subset of viable CTCs underwent 3' RNA sequencing for transcriptomic profiling. CTCs of 4/5 MBC patients (80%) exhibited single nucleotide variants (SNVs), and heterogeneity was observed at inter- and intra-patient levels. CNA profiling of CTCs from 8 patients revealed amplifications and gains of chromosomal regions hosting PIK3CA, AKT1, and PTEN. Notably, one patient presented both 10q32.31 loss and a nonsense mutation of the remaining PTEN allele, suggesting PTEN loss of function, an event potentially missed by ctDNA analysis. Integrated transcriptomic analysis highlighted patient-specific enrichment of pathways related to metabolism and RNA processing. Conclusively, single-CTC analysis enables comprehensive characterization of the PI3K/AKT/PTEN pathway, revealing molecular heterogeneity and capturing events not detectable by tumor tissue or ctDNA. This approach may enhance molecular stratification and guide the use of targeted therapies in MBC, supporting its integration into future precision oncology frameworks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.